22 completed. 22 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 22 |
| Phase 2 | 7 | Completed 7 |
Follow Acute Ischemic Stroke: new trials by email Literature Review of Acute Ischemic Stroke trials Research Report on Acute Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial HRS-7450, 0.9% sodium chloride injection - Acute Ischemic Stroke | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 64 | 2024-08-06 | 2025-09-29 |
| The Effect of GD-iExo-003 in Acute Ischemic Stroke exosomes derived from human induced pluripotent stem cell for injection, a placebo of exosomes derived from human induced pluripotent stem cell for injection - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Xuanwu Hospital, Beijing | 29 | 2024-06-05 | 2026-09-10 |
| Safety Study of PP-007 in Subjects With Acute Ischemic Stroke PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT) - Acute Ischemic Stroke | Phase 1 | Completed | Prolong Pharmaceuticals | 24 | 2024-04-24 | 2025-11-14 |
| Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke iEPCs, Placebo - Acute Ischemic Stroke | Phase 1 | Completed | Allife Medical Science and Technology Co., Ltd. | 27 | 2023-08-24 | 2025-08-12 |
| Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-1b) Mechanical thrombectomy combined with ischemic post-conditioning - Acute Ischemic Stroke, Reperfusion Injury | Phase 1 / Phase 2 | Completed | Capital Medical University | 20 | 2023-04-01 | 2025-03-18 |
| Study to Assess PK, Safety and Tolerability in Healthy Subjects QHRD106 Injection, Human Urinary Kallidinogenase, placebo - Acute Ischemic Stroke | Phase 1 | Completed | Changzhou Qianhong Bio-pharma Co., Ltd. | 56 | 2023-03-16 | 2024-07-24 |
| TPA in Acute Stroke With COVID Verus Non-COVID-19 Patients IV tPA (Activase) - Acute Ischemic Stroke | Phase 1 | Completed | Assiut University | 50 | 2022-03-01 | 2022-10-31 |
| Proteomic Study of Chuanhong Zhongfeng Capsule in the Treatment of ACI Chuanhong Zhongfeng capsule - Acute Ischemic Stroke | Phase 1 | Completed | Yingyue Ding | 20 | 2022-01-01 | 2025-03-13 |
| The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers SIM1910-09, Placebo - Acute Ischemic Stroke, Cerebral Edema | Phase 1 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 68 | 2021-12-06 | 2023-11-30 |
| Study to Assess PK, Safety and Tolerability Early in Healthy Subjects QHRD106 Injection, placebo - Acute Ischemic Stroke | Phase 1 | Completed | Changzhou Qianhong Bio-pharma Co., Ltd. | 74 | 2021-07-05 | 2024-07-24 |
| A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects LT3001 drug product, Placebo, Aspirin - Acute Ischemic Stroke | Phase 1 | Completed | Lumosa Therapeutics Co., Ltd. | 65 | 2021-03-21 | 2026-03-02 |
| Acute Ischemic Stroke Interventional Study Intravenous ACT017 1000 mg, Intravenous Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Acticor Biotech | 160 | 2019-03-06 | 2021-10-06 |
| A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) JTR-161, Placebo - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Teijin Pharma Limited | 79 | 2019-01-30 | 2022-06-30 |
| Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke DS-1040b, Placebo - Acute Ischemic Stroke, Thrombotic Disease | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 106 | 2015-09-01 | 2020-09-09 |
| Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke hUCB - Acute Ischemic Stroke | Phase 1 | Completed | China Medical University Hospital | 6 | 2015-05-01 | 2025-08-06 |
| DS1040b/Aspirin Drug/Drug Interaction Study DS-1040b, Aspirin - Acute Ischemic Stroke | Phase 1 | Completed | Daiichi Sankyo | 18 | 2014-01-01 | 2018-12-24 |
| Safety Study of the Rapid System for Acute Ischemic Stroke Rapid System - Acute Ischemic Stroke | Phase 1 | Completed | Rapid Medical | 12 | 2011-08-01 | 2013-11-05 |
| A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients Plasmin (Human) - Acute Ischemic Stroke | Phase 1 / Phase 2 | Completed | Grifols Therapeutics LLC | 40 | 2009-11-01 | 2015-10-21 |
| Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke Lu AA24493 (CEPO), Placebo - Acute Ischemic Stroke | Phase 1 | Completed | H. Lundbeck A/S | 24 | 2009-05-01 | 2011-04-20 |
| Study Evaluating Single Ascending Doses Of ILS-920 ILS-920 - Acute Ischemic Stroke | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 16 | 2009-02-01 | 2010-02-03 |
Showing 20 of 22. Sign in to see all of them.
Ischemic Stroke (22) · Stroke (4) · Brain Edema (1) · Hemorrhage (1) · Hypothermia (1) · Ischemia (1) · Reperfusion Injury (1) · Thrombosis (1)
Brain Diseases (22) · Cardiovascular Diseases (22) · Central Nervous System Diseases (22) · Cerebrovascular Disorders (22) · Nervous System Diseases (22) · Vascular Diseases (22) · Stroke (18) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Body Temperature Changes (1) · Embolism and Thrombosis (1) · Postoperative Complications (1) · Signs and Symptoms (1)
Aspirin (2) · AER-271 (1) · Clopidogrel (1) · Dabigatran (1) · Fibrinolysin (1) · Injections (1) · Ischemic Postconditioning (1) · PEGylated carboxyhemoglobin bovine (1) · Sodium Chloride (1) · Tissue Plasminogen Activator (1) · apixaban (1) · caffeinol (1)
Changzhou Qianhong Bio-pharma Co., Ltd. (2) · Daiichi Sankyo (2) · H. Lundbeck A/S (2) · Acticor Biotech (1) · Allife Medical Science and Technology Co., Ltd. (1) · Assiut University (1) · Capital Medical University (1) · China Medical University Hospital (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Grifols Therapeutics LLC (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Lumosa Therapeutics Co., Ltd. (1) · Prolong Pharmaceuticals (1) · Rapid Medical (1) · Teijin Pharma Limited (1)
China (8) · France (5) · United Kingdom (4) · United States (4) · Australia (2) · Finland (2) · Netherlands (2) · Singapore (2) · Slovakia (2) · Spain (2) · Taiwan (2) · Austria (1) · Czechia (1) · Egypt (1) · Germany (1)
Juan Li, Doctor (2) · Andrea Comenducci, MD (1) · James C. Grotta, MD (1) · Jeffrey Saver, MD (1) · Junwei Hao, MD; PhD (1) · Kirsten Gruis, MD (1) · Mimi Yeh, PhD (1) · Peter Mitchell, MD (1) · Shinn-Zong Lin, M.D.;PhD. (1) · Yongjun Wang (1)
PMID 39545461, PMID 32106339, PMID 35613802, PMID 38267188, PMID 40517620, PMID 40889891, PMID 41585378, PMID 42044230, PMID 42749369
2015 (1), 2018 (1)